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Abstract
Background: Pertussis (whooping cough) caused by Bordetella pertussis (B.p), continues to be a serious public health threat.
Vaccination is the most economical and effective strategy for preventing and controlling pertussis. However, few systematic
investigations of actual human immune responses to pertussis vaccines have been performed. Therefore, we utilized a
combination of two-dimensional electrophoresis (2-DE), immunoblotting, and mass spectrometry to reveal the entire
antigenic proteome of whole-cell pertussis vaccine (WCV) targeted by the human immune system as a first step toward
evaluating the repertoire of human humoral immune responses against WCV.
Methodology/Principal Findings: Immunoproteomic profiling of total membrane enriched proteins and extracellular
proteins of Chinese WCV strain 58003 identified a total of 30 immunoreactive proteins. Seven are known pertussis antigens
including Pertactin, Serum resistance protein, chaperonin GroEL and two OMP porins. Sixteen have been documented to be
immunogenic in other pathogens but not in B.p, and the immunogenicity of the last seven proteins was found for the first
time. Furthermore, by comparison of the human and murine immunoproteomes of B.p, with the exception of four human
immunoreactive proteins that were also reactive with mouse immune sera, a unique group of antigens including more than
20 novel immunoreactive proteins that uniquely reacted with human immune serum was confirmed.
Conclusions/Significance: This study is the first time that the repertoire of human serum antibody responses against WCV
was comprehensively investigated, and a small number of previously unidentified antigens of WCV were also found by
means of the classic immunoproteomic strategy. Further research on these newly identified predominant antigens of B.p
exclusively against humans will not only remarkably accelerate the development of diagnostic biomarkers and subunit
vaccines but also provide detailed insight into human immunity mechanisms against WCV. In particular, this work highlights
the heterogeneity of the B.p immunoreactivity patterns of the mouse model and the human host.
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Introduction
Bordetella pertussis (B.p) is a strictly obligate human pathogen and
the causative agent of a seriously contagious childhood respiratory
disease, whooping cough or pertussis, which causes 300,000 children
death mainly in developing countries and afflicts up to 40 million
children worldwide per year [1]. Vaccination is the most economical
and effective strategy for preventing and controlling pertussis. The
introduction of the first generation of pertussis vaccines in the 1950s
dramatically reduced the incidence of the disease [2]. Now, WCV
and acellular pertussis vaccines (ACV) are two main types of pertussis
vaccines that are used globally [3]. Despite the high vaccination
coverage all over the world, pertussis is still a serious contagious
childhood acute respiratory disease, especially in infants less than 6
months old [4]. Frequent pertussis outbreaks have been reported
recently [5]. Recent investigations have revealed that even older
children, adolescents and adults immunized with the vaccine or
infected previously could also be infected by the disease again and in
turn actasimportant sourcesoftransmission to young infants whoare
either non-vaccinated or too young to be vaccinated [6,7].
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Hepatitis B virus, the pathogenesis of B.p is much more complex
because a range of different virulence determinants have been
implicated [8]. B.p exists in three distinct phenotypes, virulent
Bvg+ (Bordetella virulence gene) phase, avirulent Bvg- phase and
Bvg-intermediate phase (Bvgi) controlled by the BvgAS two-
component signal transduction system. Each of the three phases is
classically characterized by the maximal expression of a subset of
Bvg phase-specific genes. These key virulence determinants of B.p
are divided into two main groups: adhesins, such as Filamentous
hemagglutinin (FHA), Peracitin (Prn), Fimbriae 2 and 3, Serum
resistance protein (BrkA), Tracheal colonization factor (TcfA); and
toxins, such as Pertussis toxin (PT), Tracheal cytotoxin (TCT),
Dermonecrotic toxin (DNT) and Adenylate cyclase (CyaA).
Almost all of the known virulence determinants are virulent
Bvg+ phase-specific genes. Numerous investigations of these
virulence determinants have vastly contributed to our understand-
ing of immunity mechanisms against B. p infection and
immunization with pertussis vaccines [8]; however, the basis of
the protective immunity of these identified virulence factors is not
fully understood, and some unknown antigens remain to be further
investigated. Therefore, the exact immunity mechanism of B. p in
human hosts is still far from clear.
It should be noted that B. p is a strictly obligate human pathogen
with no known animal and environmental reservoir; experimental
infection of animal models only occurs when these animals are
immunized with large inoculating doses of B. p. Compared to
pertussis patients, most animal models of B.p produce different
clinical symptoms, including lack of cough, symptomatic upper
respiratory infection and whoop, and the consistent production of
pertussis pneumonia [9,10]. Hence, there may be many
differences between human hosts and animal models. Further-
more, paroxysmal cough, the most characteristic symptom of
pertussis infected infants, is not observed in most animal models
[10]. Additionally, based on the strikingly converse serum
antibody responses between mice and children immunized with
WCV against many main B.p protective antigens such as PT and
FHA, an earlier investigation has shown that the murine model as
a main pertussis animal model should not be globally applied to
evaluate the protective efficacy of pertussis vaccines comprising
these antigenic components [11]. Thus, these evidences suggest
that these animal models are limited in their degree of sensitivity to
accurately reflect events occurring during pertussis infection or
vaccination in human hosts. Therefore, there is a growing effort to
elucidate human immune responses against B. p infection and
immunization with pertussis vaccines.
A large numbers of investigations have utilized immunopro-
teomic technology, combining 2-DE with immunoblot analysis of
antigenic proteins, which are globally applied to reveal immune
responses of the host against pathogen antigens as well as to
identify suitable prognostic and diagnostic biomarkers and
pathogenic targets for developing new drugs and vaccines
[12,13,14,15,16,17,18,19,20]. According to the theory of reverse
vaccinology, total membrane enriched proteins (TMPs) and
extracellular proteins (ECPs) of bacterial pathogens primarily
mediate many critical biological cellular processes, including host-
pathogen interactions, virulence and pathogenesis, survival of the
pathogen in the intracellular environment and the evasion of the
host immune system, and are frequently main targets of the host
immune system; hence, these proteins are certainly useful
candidate antigens for vaccine and diagnostic development
[21,22,23]. Thus, it is remarkably valuable to screen suitable
vaccine candidates from these two sub-proteomes of B. p.
Recently, systematic identification of antigenic proteins from the
whole proteome of B. p in infected or immunized mouse serum has
been reported [20]. However, a full understanding of the
repertoire of human immune responses against pertussis has been
limited because of a lack of detailed knowledge of the entire
antigenic composition of WCV recognized by human hosts. In the
present study, we used a classic immunoproteomic strategy to
investigate the complete set of antigenic proteins from TMP and
ECP preparations of Chinese WCV strain 58003 and have
provided a complete immunoproteomic reference map for future
studies of B. p. This report is the first to precisely characterize the
repertoire of human serum antibody responses against WCV, and
it will open the door toward the downselection of ideal protective
antigens for incorporation into pertussis subunit vaccines. Finally,
the data obtained from our study will significantly accelerate the
development of new diagnostic markers and a new generation of
B. p subunit vaccines.
Materials and Methods
2.1 Ethics Statement
The study protocol was approved by the Ethics Committee of
Shanghai Jiao Tong University and conforms to the principles
outlined in the Declaration of Helsinki. The ten hyper-immune
serum samples from children immunized with WCV that were
kindly donated by Professor Zhang Shu-Min (Division of Serum,
National Institute for Control of Pharmaceutical and Biological
Product) were pooled together. Negative control sera were
randomly obtained from two unvaccinated infants in one local
children’s hospital with waiver of consent, which the Ethics
Committee of Shanghai Jiao Tong University approved. However,
because of the requirement of these participants’ parents, nearly all
of serum samples were anonymous and no personal information
was collected. Thus, written, informed consent was not obtained
from these participants.
2.2 Preparation of TMPs and ECPs of B.p Chinese WCV
strain 58003 for 2-DE
High-density whole cell culture and culture supernatant of
Chinese WCV strain 58003 (6610
9 cell/ml) were kindly provided
by Xiang Mei-Juan (Department of Pertussis Whole-Cell Vac-
cines, Wuhan Institute of Biologic Products). The Chinese WCV
strain 58003 was grown in Stainer-Scholte liquid medium (protein-
free) at 37uC. Culture supernatant was collect by centrifugation for
15 min at 4,0006ga t4 uC and filtered through a 0.22 mm
membrane to remove residual bacteria. Then, the filtrate was
treated with chilled 15% TCA in an ice-bath for 30 min to
precipitate proteins. After centrifugation at 10,0006g for 10 min
at 4uC, the precipitated proteins were washed three times with
chilled acetone to remove TCA and were naturally air-dried.
Finally, the ECPs were stored at 280uC for subsequent analysis.
TMPs of Chinese WCV strain 58003 were extracted as
previously described by Zhang et al [16]. In brief, the bacterial
cell pellet was resuspended in solution A containing 80 mm Tris–
HCl, pH 7.4 and 1.2 M NaCl and sonicated in an ice-bath. The
solution was centrifuged at 10,0006g for 20 min to remove
unbroken cells and debris. Next, one-third volume of solution B
containing 40 mM Tris–HCl, pH 7.4, 600 mM NaCl and 4%
Triton X-114 (Amresco, USA) was added, followed by incubation
on ice for 1 h with frequent vortexing. After incubation at 30uC
for 3 min, the sample produced an upper aqueous phase and a
lower detergent phase by centrifugation at 13006g for 10 min at
room temperature. TMPs in the detergent phase were precipitated
with 10 volumes of chilled acetone overnight at 220uC. By
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dried and were stored at 280uC for subsequent analysis.
Prior to 2-DE, TMPs and ECPs were both further purified by
using a 2-DE clean-up kit (GE Healthcare).
2.3 2DE-PAGE
2DE-PAGE was performed as previously described by zhang et
al [16,19]. 7 cm Immobiline DryStrip (IPG, pH 4–7; Bio-Rad)
dissolving 150 mg ECPs in a total volume of 150 mL rehydration
buffer (8 M urea, 2% CHAPS, 50 mM DTT, 0.2% Bio-Lyte 4–7
Ampholyte, 0.002% Bromophenol Blue; Bio-Rad) was rehydrated
for 13 h at 20uC and IEF was performed in a PROTEAN IEF cell
(Bio-Rad) under the running conditions as following: 250 V for
0.5 h, 500 V for 0.5 h, 4000 V for 3 h, and 4000 V for 20000 Vh.
Similarly, 13 cm Immobiline DryStrip (IPG, pH 4–7; GE
Healthcare) dissolving 350 mg TMPs in a total volume of
250 mL rehydration buffer (7 M urea, 2 M thiourea, 2% CHAPS,
50 mM DTT, 0.2% Bio-Lyte 4–7 Ampholyte, 0.002% bromo-
phenol blue; Bio-Rad) was rehydrated for 14 h at 20uC and IEF
was performed in a Multiphor II IEF system (GE Healthcare)
under the running conditions as following: 500 V for 4 h, 1000 V
for 1 h, 2000 V for 1 h, 4000 V for 1 h, and 8000 V for
36000 Vh. After electrophoresis, each IPG strip was washed for
15 min in equilibration buffer A (375 mM Tris-HCl, 6 M urea,
2% SDS, 2% w/v DTT; Bio-Rad) and in equilibration buffer B
(375 mM Tris-HCl, 6 M urea, 2% SDS, 2.5% w/v iodoaceta-
mide; Bio-Rad). The IPG strips were then placed onto a 12.5%
SDS-PAGE gel and the second dimensional separation was
performed in two steps at 10uC: 80 V/gel for 30 min and
120 V/gel until the tracking dye reached the bottom of the gels.
One gel used as a reference proteome map was Coomassie blue
stained with CBB-G250, and the other duplicated gel was
transferred onto PVDF membrane for subsequent immunoblot
analysis.
2.4 Immunoblot analysis of 2-DE
The 2DE-PAGE separated proteins were electroblotted onto
PVDF membrane (GE Healthcare) using a semidry transfer system
(Hoefer TE 77, GE Healthcare) for 1 h with a current of 1 mA/
cm
2. The PVDF membranes were blocked with 5% w/v defatted
milk in TBS-T (50 mM Tris-Cl, pH 7.4, 200 mM NaCl, 0.05%
w/v Tween-20) for 2 h at room temperature. Then, the
membranes were incubated with a 1:1000 dilution of pooled
serum at 4uC overnight and subsequently washed four times with
TBS-T for 5 min. Next, the membranes were further incubated
with a 1:2000 dilution of peroxidase-labeled rabbit anti-human
IgG (Jackson, USA) for 1 h at room temperature. Finally, the
membranes were washed five times with TBS-T for 5 min and
developed with 3,39-diaminobenzidine (DAB, Sigma) substrate
until optimum color development was observed. Each immuno-
blotting experiment was performed in duplicate.
2.5 MALDI-TOF-MS analysis and database search
Spots were excised from the 2D coomassie blue-stained gels and
sent to Shanghai GeneCore BioTechnologies Co., Ltd for tryptic
in-gel digestion and MALDI-TOF-MS with a Voyager DE Pro
MALDI-TOF mass spectrometer (ABI). Peptide mass fingerprint
(PMF) data was searched against the NCBI database in MASCOT
server (http://www.matrixscience.com) for sequence match. The
MASCOT search parameters were as follows: Bacteria (Eubacte-
ria); one missed cleavage by trypsin digestion; fixed posttransla-
tional modification (oxidized methionine); peptide charge (posi-
tive); peptide mass tolerance (6100 ppm) and fragment mass
tolerance (60.5 Da). The MASCOT probability score for the
match, molecular weight (MW), isoelectric point (pI), number of
peptide matches and percentage of the total amino acid sequence
covered by the peptides were comprehensively analyzed for
confident spot identification. Successful protein identification must
meet the following criteria: these peptides defined as significant hit
by MASCOT probability analysis and the MASCOT probability
score of these peptides for the match higher than 60; at least 6
matching peptides and amino acid sequence coverage more than
20%.
2.6 Bioinformatic analysis
In addition to spot identification by PMF, a detailed analysis of
these identified immunoreactive proteins was performed using a
variety of bioinformatics tools. We adapted a previously developed
approach with some modifications to predict subcellular localiza-
tion of gram-negative bacterial proteins [24]. Protein families were
identified using Pfam (http://www.sanger.ac.uk/Software/Pfam/).
The theoretical molecular weight and isoelectric point were
calculated using the compute pI/MW tool (http://www.expasy.
org/tools/pi_tool.html/). The Codon Adaptation Index (CAI) of
each protein was evaluated with the JCAT tool (http://www.jcat.
de).
2.7 Previous proteomic data and transcriptional profiling
of other B.p vaccine strains
In addition to human immunorpteome of B.p Chinese WCV
strain 58003 in the present study, Murine immunoproteomes of
B.p vaccine strains Saadet and Tohama recently performed by
Emrah altindis et al were directly obtained from their published
study [20]; The outer membrane vesicles (OMV) proteome and
Surfaceome of B.p vaccine strain Tohama CIP 8132 was derived
from Daniela Hozbor et al [25,26]; Global expression profiling of
the B.p strain Tohama was obtained from the AarrayExpress
database in the EBI (The experimental protocol and data analysis
of these microarray are compliant with current MIAME guideline.
The detailed MIAME information of these microarray is shown
in http://www.ebi.ac.uk/microarray-as/aer/details?class=MAGE.
Experiment_protocols&criteria=Experiment%3D531022681&context
Class=MAGE.Protocol&templateName=Protocol.vm), and all raw
and processed microarray data are available in the AarrayExpress
database. Accession Number: E-TABM-31) [27].
Results
3.1 2-DE proteome profiling of TMPs and ECPs of B.p
Chinese WCV strain 58003
According to preliminary experiment results, the vast majority
of immunoreactive proteins were restricted between pH 4.0 and
7.0 (data not shown). Therefore, our experimental strategy utilized
2-DE and immunoblotting analysis of TMPs and ECPs of WCV
strain 58003 with proteins resolved between pH 4.0 and 7.0.
T h e2 - D Ep r o f i l e so fT M P sa n dE C P so fB.p WCV strain 58003
revealed more than 350 and 60 protein spots, respectively, on the gels
with pIs ranging from 4.0 to 7.0 and molecular masses ranging from 10
to 160 kDa (See Fig. 1A–2A). After performing immunoblot analysis,
the corresponding immunoreactive protein spots were excised from
Coomassie blue-stained gels for protein identification by PMF.
3.2 Identification of human immunoreactive proteins
from TMPs and ECPs of B.p Chinese WCV strain 58003
The application of MALDI-MS approach resulted in successful
identification of 41 immunoreactive protein spots corresponding to
30 distinct proteins which included 23 TMPs and 11 ECPs with
Human Immunoproteome of WCV
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reactive proteins of B.p WCV strain 58003 are listed in Table S1
and their positions are shown on the reference 2D proteome and
representative immunoproteome maps (See Fig. 1–2). A few weak
reactions were also observed with negative sera, but none of these
immunoreactive proteins reacted with the negative sera (See
Figure S1). The average experimental molecular mass of all the
identified proteins was 49.6 kDa, and their average pI was 5.84.
The smallest protein identified was a putative ABC transporter
ATP-binding protein of 29.6 kDa, while the largest protein was
Figure 1. 2-D proteome reference map and representative immunoblot of TMPs of B.pertussis Chinese WCV strain 58003. TMPs were
separated by IEF at pH 4–7 in the first dimension and then by 12.5% SDS-PAGE in the second dimension. Gels were either Coomassie blue-stained
(Fig. 1 A) or immunoblotted with a 1:1000 dilution of pooled immune sera from vaccinated children (Fig. 1B). The protein spots of interest were
excised individually for identification by PMF. The spot numbers refer to the identified immunoreactive proteins listed in Table S1.
doi:10.1371/journal.pone.0013915.g001
Figure 2. 2-D proteome reference map and representative immunoblot of ECPs of B.pertussis Chinese WCV strain 58003. ECPs were
separated by IEF at pH 4–7 in the first dimension and then by 12.5% SDS-PAGE in the second dimension. Gels were either Coomassie blue-stained
(Fig. 2A) or immunoblotted with a 1:1000 dilution of pooled immune sera from vaccinated children (Fig. 2B). The protein spots of interest were
excised individually for identification by PMF. The spot numbers refer to the identified immunoreactive proteins listed in Table S1.
doi:10.1371/journal.pone.0013915.g002
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pI 4.07 for OmpP to pI 7.08 for PBP. In particular, the four
proteins Prn, BrkA, OmpP and Sbp were identified as immuno-
genic proteins in both the TMP and the ECP preparations. As
frequently described for many pathogens, multiple different spots
in the same gel with distinct charges or molecular masses were
often identified as the same protein encoded by a single gene. The
most frequent examples in this study were Prn (3 different spots),
BrkA (3 spots) and GroEL (2 spots).
Discussion
Here, by combining the present study with previous murine
immunoproteomic studies of B.p, we discovered approximately 30
highly specific immunoreactive proteins directed against human
hosts. These human immunoreactive proteins of WCV identified
in this work can be divided into three main groups (See Table S2).
The first group is composed of the seven known immunoreactive
antigens including Prn, BrkA, GroEL, BipA, PtlF and two porins,
OmpP and OmpQ, which have previously been well-character-
ized in B. p. With the exception of the Bvgi- phase-specific gene
BipA, all other known pertussis antigens are virulent Bvg+ phase-
specific genes associated with the pathogenesis and virulence of B.
p. The immunoreactive proteins of the second group can be
divided into two subgroups, including those commonly conserved
antigenic proteins that have already been shown to be highly
immunogenic in more than four distinct pathogenic bacteria such
as Ldh, GdhA, SdhA, GAPDH, EF-Tu, EF-Ts and putative ABC
transporter ATP-binding protein, and another uniquely antigenic
proteins in one (or occasionally several) pathogenic bacteria, such
as NuoD, MetC, SucC, Icd, MinD, PBP, LivJ, putative ABC
transport solute binding protein and putative alcohol dehydroge-
nase. Finally, the third group is composed of several previously
unidentified immunoreactive proteins, such as Sbp and three
hypothetical proteins (BP0250, BP2818 and BP3575). Further-
more, a total of 18 human immunoreactive proteins that include
the seven known pertussis antigens and newly identified antigens
(putative ABC transport ATP binding protein, putative ABC
transport solute binding protein, hypothetical proteins BP2818,
PBP, EF-Tu, EF-Ts, Ldh, SucC, LivJ and SdhA) have been
previously found in the Surfaceome or OMV proteome of B. p,
indicating that these surface antigens could serve as predominant
targets recognized by the host immune system and, hence, induce
strong host immune responses.
However, with the exception of Prn and BrkA, most of other
known protective antigens such as PT, FHA, Fimbriae 2 and 3,
and main pertussis virulence factors including TCT, LPS, CyaA
and DNT always seem to escape detection by 1-D or 2-D
immunoblotting [20,28]. The explanation for this phenomenon
might be due to the limited resolution capacity of 1-D and 2-D
SDS-PAGE and mass spectrometric identification as well as to
particular properties of these antigens, such as high molecular
weight (FHA: 367 kDa and CyaA: 178 kDa), unusually basic
proteins (Fimbriae 3: pI 9.10) and too low protein concentration
(PT) [28].
4.1 Known B.p immunoreactive antigens
ACVs containing Prn can provide more effective protection
against pertussis than ACVs without Prn [29]. Many studies from
vaccine trials have provided abundant evidence that Prn serves as
the most important adhesin playing an essential role in B.p
adherence to host cells [30,31]. In addition, Prn elicits stronger
and more long-lasting antibody responses than other protective
antigens such as PT and FHA, and thus it might be the protective
antigen primarily recognized by immunoblot assays [32]. At the
molecular level, Prn contains two repeat regions, GGxxP and PQP
repeats, both of which have been identified as B-cell epitopes and
elicit strong antibody responses in both humans and mice [33].
Like Prn, surface-exposed BrkA belongs to the same autotran-
sporter family. The members of the autotransporter family include
adhesins (FHA and Prn), toxins (virulence-activated genes 8,
Vag8), invasins (TcfA) and proteases (Autotransporter subtilisin-
like protease, SphB1). The essential function of these autotran-
sporters is to direct their own export to the outer membrane or
extracellular space. In addition to its main role in resistance of B.p
to human immune serum complement-mediated killing, BrkA has
been reported to contribute to the adherence and invasion of B.p
to host cells in vitro and in vivo in a murine model of respiratory
infection [34,35]. Two porins, OmpP and OmpQ, are the
predominant integral outer membrane proteins of B. p [36,37].
Previous studies had shown that OmpP should be regarded as a
potentially suitable subunit vaccine component, for it can not only
serve as a highly conserved adhesin mediating adherence of B.p or
B.parapertussis (B.pp) to human bronchial epithelial cells in vitro but
also induce long-term high titers of bactericidal antibodies in
immunized mice [38,39]. Although the exact function of the Bvgi
phase remains to be determined, this phase where conditions may
be intermediate between the host environment and the environ-
ment outside appears to play a vital role in respiratory
transmission [40]. BipA, the typical Bvgi-phase-specific gene, is
highly similar to many well-characterized bacterial adhesins,
intimins and invasins, and it might be associated with initial
adherence and colonization of B.p to the respiratory tract of
human hosts [41]. Thus, it was not surprising that BipA was found
to be recognized by the human immune system and identified as a
human immunoreactive protein of B.p in this work. In addition to
Fimbriae 2 and 3, Prn, FHA and PT, which have multiple
antigenic variations, BipA and OmpQ also have two different
antigenic variations. In general, the variations in these antigens of
currently circulating strains are distinct from those of vaccine
strains of B.p [42,43]. A plausible explanation is that these
circulating strains are less affected by strong vaccine-driven
selective pressures and are preferentially selected; thus, the
antigenic divergence observed between circulating strains and
vaccine strains may have gradually decreased the efficacy of these
vaccines and led to the reemergence of pertussis. Consequently,
BipA and OmpQ could be used as novel potential protective
antigen candidates. Furthermore, GroEL has been previously used
as a major target dominantly recognized by the immune system of
infants vaccinated with WCV [44]. As one main component of the
type IV secretion system of B.p, Not only was PtlF identified in the
Surfaceome of B. p, but PtlE was also previously described to be
immunodetected in B. p whole-cell lysates by using a specific
mouse polyclonal antibody against recombinant PtlF protein [45].
4.2 Novel B.p immunoreactive proteins previously
identified in other pathogens
Because of their wide immunogenicity among at least nine
different pathogens, Elongation factor EF-Tu, EF-Ts and GAPDH
represent the most typical examples of commonly conserved
antigenic proteins. For instance, EF-Tu, a very abundant protein,
has been shown to be highly immunogenic in Anaplasma marginale
[46], Borrelia hermsii [47], chlamydia trachomatis [48], Bacillus anthracis
[49], Clostridium perfringens [50], Shigella flexneria [51], staphylococcus
epidermidis [52], Francisella tularensis [53,54,55] and Bartonella quintans
[56]. In addition, it has been reported that cell surface-associated
EF-Tu of many distinct bacteria show multiple activities binding to
various mammalian proteins including mucin (Lactobacillus johnsonii)
Human Immunoproteome of WCV
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factor H (Pseudomonas aeruginosa) [59]. Due to these biological
binding activities, EF-Tu has been identified as an immunodomi-
nant surface antigen in Anaplasma marginale, Staphylococcus aureus,
Bacillus cereus, Mycobacterium chelonae and Actinobacillus pleuropneumo-
niae, and it has strong potential to be a promising vaccine
candidate due to its ability to induce high-level host immune
responses [15,60,61,62]. Interestingly, most of these newly
identified B.p immunoreactive proteins are housekeeping enzymes
that might be ideal diagnostic biomarkers or vaccine candidates
due to their high antigenic conservation among different virulent
strains of certain pathogens and even many distinct pathogens. As
the best examples of this type of housekeeping enzyme, GAPDH
has been shown to be highly immunogenic in more than nine
pathogenic bacteria including Paracoccidioides brasiliensis [63],
Lactococcus garvieae [64], staphylococcus epidermidis [52], Streptococcus
pneumoniate [65], Candida albicans [66,67], Streptococcus suis [16],
Francisella tularensis [54], Actinobacillus pleuropneumoniae [15], Haemon-
chus contortus [68] and Group A streptococcus [69]. There are several
experiments to show that GAPDH represents high levels of
conserved immunogenicity, and hence, it has also been recognized
as an important cross-strain protective antigen against Schistosoma
mansonii, Edwardsiella tarda, Onchocerca volvulus, Streptococcus pyogenes
and Bacillus spp [61,65,70,71,72]. The two typical examples of
these uniquely antigenic proteins, PBP and Livj, have been already
strictly identified as antigenic protein in Shigella flexneri and Brucella
abortus, respectively [18,73,74]. PBP as surface-associated protein is
mainly involved in the synthesis of the peptidoglycan layer of
bacterial cell wall and is a main target of b-lactam antibiotics.
Several investigations showed that PBPs have been required for
virulence of many important human pathogens including
Mycobacterium tuberculosis, Group A Streptococcus, Group B streptococcus
(GBS) and Streptococcus pneumonia [75,76,77,78]. LivJ representing
the most abundant transport protein has been characterized in the
extracellular proteomes of E.coli BL21 and W3110 strains, showing
that LivJ could also serve as extracellular protein released outside
the cell and thus recognized by host immune system [79]. In
addition to presence in the Surfaceome and OMV proteome of B.
p, putative ABC transport solute binding protein as a newly
identified low-iron-induced protein displays differential protein
expression levels between iron-excess and iron-starvation condi-
tions, and it might be closely associated with B.p virulence [80].
Furthermore, putative ABC transport solute binding protein of
Neisseria meningitidis has been regarded as a potentially new
protective antigen for incorporation into multicomponent menin-
gococcal vaccines; it was not only found to be exposed on the
bacterial surface and well conserved across a range of meningo-
coccal circulating strains, but also strongly reactive with sera from
31 convalescent young children infected with meningococcal
disease [23,81].
4.3 B. p immunoreactive proteins identified for the first
time in this study
It is notable that members of the third group, putative 2-
hydroexyacid dehydrogenase, Sbp, amino acid-binding periplas-
mic protein, putative exported solute binding protein and three
hypothetical proteins (BP0250, BP2818 and BP3575) are reported
to be immunogenic proteins for the first time in this study. Among
them, BP2818 and putative exported solute binding protein were
included in the OMV proteome of B. p, and only Sbp was
identified as an immunogenic protein in both TMP and ECP
fractions, indicating its highly reliable immunogenicity. The D-
isomer specific 2-hydroxyacid dehydrogenase exhibits more than
50% sequence similarity to putative 2-hydroxyacid dehydrogenase
which was identified as one of the antigenic proteins binding to
serum antibody obtained from treponema pallidum-infected
rabbits [82]. Pfam analysis revealed that BP2818 and BP3575
belong to the Lipoprotein_9 and ANF_receptor families, respec-
tively. The bacterial Lipoprotein_9 family contains several
antigenic members that may be involved in bacterial virulence,
such as three highly immunoreactive antigens of Pasteurella
haemolytica: plpA, -B and –C [83]. The ANF receptor family also
includes extracellular ligand binding domains of a wide range of
receptors. Similarly, Sbp, amino acid-binding periplasmic protein
and putative exported solute binding protein are also identified as
members of the SBP_bac_1, SBP_bac_3 and SBP_bac_7 families
of bacterial extracellular solute-binding proteins, respectively,
indicating their potential for secretion into the extracellular space.
Based on the theory of reverse vaccinology, the vast majority of
these immunogenic proteins of the third group annotated as
exposed on the cell surface by Gene Ontology and Pfam or
included in the OMV proteome of B. pertussis should be the most
likely suitable vaccine candidates because these proteins are easily
recognized by the host immune system and therefore stimulate
strong immune responses [21,22,23].
4.4 Human versus murine immunoproteome of B.p
vaccine strains
Finally, apart from other similar findings such as those in
Helicobacter pylori and Francisella tularensis, which showed high
similarities in antigen recognition between humans and mice
[54,84], the comparison of the human immunoreactive proteins of
B. p identified in our present work with previously identified
murine immunoreactive proteins of B. p revealed many similarities
but many more noticeable differences, reflecting heterogeneous
immunoreactivity patterns between the human host and the
murine model. Surprisingly, only the four human immunoreactive
proteins, Prn, BrkA, GroEL and EF-Tu, were also immunode-
tected by serum from immunized or infected mice. Furthermore,
the other human immunodominant antigens like OmpP, OmpQ,
BipA and EF-Ts were not recognized by murine immune sera.
4.4.1 Theoretical Expression Abundance and Gene
Expression Profiling. In order to analyze the main reasons
resulting in the heterogeneous immunoreactivity patterns, we
further evaluated the differences in theoretical expression
abundance and experimental gene expression profiling between
the human and murine immunoreactive proteins of B. p using the
JCAT tool and DNA microarray data (Shown in Fig. 3). The CAI
values of these human and murine immunoreactive proteins of B. p
ranged from 0.404 to 0.850 (mean: 0.641) and from 0.429 to 0.850
(mean: 0.664), respectively, and were not statistically different (P-
value=0.395). In accordance with the CAI values, transcript
abundances of the human and murine immunoreactive proteins of
B. p ranged from 0.27 to 4.44 (mean: 1.229) and from 0.385 to
5.00 (mean: 1.303), respectively, and were not statistically different
(P-value=0.7665). Thus, the results from both the CAI values and
the gene expression profiling showed that the two groups of
immunoreactive proteins shared same level of expression.
4.4.2 Subcellular Localization. The sequences of these
identified human immunoreactive proteins in B.p were analyzed
using a combination of several algorithms and Gene Ontology in
order to predict subcellular localization as described in our
previous study with some modifications (See Table S1) [24]. A
total of 37% (11/30) are predicted to localize to OuterMembrane/
OM-associated, 47% (14/30) to cytoplasm, 13% (4/30) to
secretory and 3% (1/30) are of unknown localizations. The
subcellular localization of all murine immunoreactive proteins was
as follows: 52% to cytoplasm, 16% to OuterMembrane/OM-
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(See Fig. 4). Comparison of the subcellular localizations of the
human and murine immunoreactive proteins demonstrated
moderate similarities but somewhat disparate results mainly
focused on the differential percentage of OuterMembrane/OM-
associated proteins and proteins of unknown localization.
4.4.3 Comparison of the human and murine
immunoproteomes of B.p with the Surfaceome and OMV
proteome of B.p vaccine strains. In addition to comparing
the two immunoproteomes to one another, we also compared the
human and murine immunoproteomes of B. p with the previously
reported Surfaceome and OMV proteome of B. p vaccine strains
in Argentina, respectively (See Fig. 5 and Table S2) [25,26]. A
total of sixty percent (18/30) of the human immunoproteome of B.
p were also present in the Surfaceome (46%; 14/30) and OMV
proteome (43%; 13/30) of B. p, including all seven known pertussis
antigens, several dehydrogenases, EF-Ts, EF-Tu, PBP and ABC
transport solute-binding protein. By contrast, only 24% (6/25) of
all murine immunoreactive proteins were present in the
Surfaceome (20%; 5/25) and OMV proteome (24%; 6/25) of B.
p, including Prn, BrkA, GroEL and serine protease.
As described above, the CAI values and gene expression
profiling indicated that there was no correlation between the
significant differences of the two immunoproteomes of B. p and the
expression levels of these immunoreactive proteins. In addition,
the differences of subcellular localization between the human and
murine immunoreactive proteins were not remarkable. As these
reasons above can be excluded, the precise reasons for the
apparent differential immunoreactivity patterns might be due to
the following determining factors:
1. Human immune system versus murine immune system. First,
the most likely reason for this differential pattern is that certain B.
p antigens may be recognized differently by the murine and
human host immune systems, which contributes to the observed
Figure 3. Comparison of the CAI values and gene expression profiling between the murine and human immunoproteomes of
B.pertussis vaccine strains. Statistical analysis was performed with the R language.
doi:10.1371/journal.pone.0013915.g003
Figure 4. Subcellular localization distribution of these identified immunoreactive proteins in the murine and human
immunoproteome of B.pertussis vaccine strains.
doi:10.1371/journal.pone.0013915.g004
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remarkably different immune responses between a mouse model
and a human host have been reported. Keith Redhead had
previously doubted the true value of the pertussis murine model
for evaluating pertussis vaccine efficacy because the murine model
and children vaccinated with WCV produced significantly
differential antibody responses against several main protective
antigens such as PT and FHA [11].
2. Pooled human and murine immune sera versus individual
human and murine immune serum. With respect to vaccine and
diagnostic applications, the biggest advantage of the pooled
immune sera widely used in immunoproteomic analysis is to
preferentially screen a small number of antigens with the highest
level or the most conservative immunogenicity. However, other
proteins eliciting weaker antibody responses or exclusively reactive
with certain individual immune serum might be swamped. On the
contrary, regarding inter-individual variation, increasing the
number of individual immune serum leads to the identification
of a larger number of antigens uniquely recognized by individual
serum, and this might dramatically improve the similarities
between the human and murine immunoproteomes of B.p.
However, based on experimental goals, we and Emrah et al.
chose pooled human and murine immune sera, respectively,
instead of immune serum from a single individual. Therefore,
using pooled human and murine immune sera might have
contributed to the notable differences.
3. Chinese vaccine strain versus Turkey vaccine strain. Despite
the high level of conservation of the whole genome among the
majority of B.p strains [85], there is still a limited number of
genomic divergences between B. p strains affecting certain key
strain-specific protein and antigenic virulence factors [86], which
may in part account for the discrepancy. For example, with the
murine immunoproteome of B. p vaccine strain Saadet in Turkey,
some newly identified antigens were more similar to those of two
closed species of B.p, B.pp and B. bronchiseptica (B.B). In addition,
Tohama I is the only B. p strain with a completely sequenced
genome, and it is still used as the main B. p reference genome to
date. However, it was recently found that several conserved
genomic fragments among these B. p circulating isolates were
deleted from Tohama I but present in B.pp and B.B, suggesting
that Tohama I might not be a good representative strain of the B. p
species [87]. The unsuitable reference genome of B. p might thus
also account for the differences.
4. Subcellular fractions versus Whole cell fraction. Subcellular
fractionation combining with high-resolution 2D-PAGE is usually
an efficient approach significantly reducing the sample complexity
from thousands of proteins in the whole cell fraction to hundreds
of proteins in each subcellular fraction. In this study, in addition to
two known protective antigens (Prn and BrkA) and two previously
confirmed pertussis antigens (GroEL and EF-Tu) identified in the
murine immunoproteome (whole cell fraction) and human
immunoproteome (TMPs and ECPs), only another three con-
firmed antigens (OmpP, OmpQ and PtlF) were additionally
identified in the human immunoproteome of B.p. However, none
of other known protective antigens (PT, FHA, Fimbiae 2 and 3)
and main virulence factors (Type-III secretion proteins, DNT,
TCT, CyaA, TcfA, LPS and Vag8) was identified in the two
immunoproteomes or Surfacome and OMV proteome of B.p.A s
described above, there is not big difference of the identified known
pertussis antigens between the two immunoproteoms of B.p.O n
the contrary, total 11 (37%; 11/30) newly identified human
immunoreactive proteins and only 3 (12%; 3/25) newly identified
murine immunoreactive proteins were present in the Surfaceome
or OMV proteome of B.p. The obvious differences between these
Figure 5. Venn diagram demonstrating the striking differences between the comparison of the murine or human immunoproteome
with the Surfaceome or OMV proteome of B.pertussis vaccine strains, respectively. Detailed information is shown in Table S2.
doi:10.1371/journal.pone.0013915.g005
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might be due to the reason that some low abundance proteins
easily swamped by high abundance proteins in whole cell fraction
can be effectively separated and immunodetected in TMPs and
ECPs. Therefore, the sample preparation methodologies, which
have significant effect on these newly identified human and murine
immunoreactive proteins of B.p but not on these known pertussis
antigens, should be also one of the main factors resulting in the
apparent differences between the two immunoproteoms of B.p.
In summary, our results provide the first whole antigenic
proteome profile of WCV and the repertoire of human antibody
responses against WCV. These identified immunoreactive proteins
notably include many previously unidentified antigens and they
will pave the way for understanding the immunogenicity and
pathogenesis mechanisms of B. p. Furthermore, they are regarded
as suitable prognostic and diagnostic biomarkers as well as
pathogenic targets for the development of new drugs and vaccines
against pertussis. Importantly, this study also highlights the striking
differences between the humoral immune responses of the mouse
model and the human host.
Supporting Information
Figure S1 2-D control immunoblot of ECPs and TMPs of B.
pertussis Chinese WCV strain 58003.
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